Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC

CAMBRIDGE, Mass., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the first results from the Phase 1 study of AG-120 in patients with IDH1-mutant positive advanced solid tumors will be presented in an oral presentation and featured in the press program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5-9, 2015, in Boston.

"We look forward to sharing the first clinical data for AG-120 in patients with advanced solid tumors as we continue to understand the potential of this investigational medicine," said Chris Bowden M.D., chief medical officer at Agios. "This is an important step toward our long-term vision of making a difference for people with a broad range of hematologic and solid tumor cancers that harbor IDH mutations."

Title: The First Reported Results of AG-120, a First-in-class, Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of Patients with Advanced IDH1-Mutant Solid Tumors, Including Gliomas

Plenary Session Date & Time: Sunday, November 8, 2015, at 8:00 a.m. ET

Session: Advances in Targeted Therapy

Press Program Date & Time: Sunday, November 8, 2015, at 10:30 a.m. ET

Presenter: Howard A. Burris, III, M.D., Sarah Cannon Cancer Center, Nashville, Tennessee

Location: Hynes Convention Center

Investor Lunch and Webcast Information

Agios will host an investor lunch on Sunday, November 8, 2015 in Boston to review data presented at the conference, additional event details to come. The event will be webcast live and can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for approximately 30 days following the presentation.

About Agios

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in cancer metabolism and rare genetic disorders of metabolism in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging the company's knowledge of metabolism, biology and genomics. For more information, please visit Agios' website at www.agios.com.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.